----
Current ValuationThe current P/E ratio is -0.08, within the reasonable range, cheaper than 28.77% of the time in the past 3 years, and the industry ranks 67/255, the industry Median -1.26.
-0.0825xP/E
--Stock price
-0.0825xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.91x
- Typical range
- -2.52x–-0.08x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -56.67x | 148.12% | $59.17B |
BAYRYUSBayer | -23.84x | -- | $48.10B |
BAYZFUSBayer Aktiengesellschaft | -23.89x | -- | $48.20B |
VTRSUSViatris | -49.33x | 107.68% | $20.26B |
ELANUSElanco Animal Health | -57.54x | 129.36% | $11.45B |
VREOFUSVIREO GROWTH INC | -132.75x | -- | $8.91B |
AXSMUSAxsome Therap | -46.01x | 25.55% | $8.82B |
CURLFUSCuraleaf Holdings, Inc. | -138.15x | -- | $7.19B |
BLTEUSBelite Bio | -60.78x | 29.87% | $6.22B |
MANEUSVeraDermics | -52.44x | 97.44% | $5.47B |
DFTXUSDefinium Therapeutics | -14.01x | 54.37% | $4.96B |
EWTXUSEdgewise Therapeutics | -21.51x | 137.29% | $4.24B |
RGCUSRegencell Bioscience | -311.21x | -- | $3.64B |
AMLXUSAmylyx Pharmaceuticals | -23.22x | 1.76% | $3.53B |
TARSUSTarsus Pharmaceuticals | -69.08x | 205.82% | $3.21B |
ELVNUSEnliven Therapeutics | -28.35x | 6.39% | $3.00B |
MBXUSMBX Biosciences | -24.59x | 31.12% | $2.56B |
SUPNUSSupernus Pharma | -22.57x | 70.59% | $2.48B |
BHCUSBausch Health | -2.06x | 305.55% | $2.26B |
PHVSUSPharvaris BV | -11.00x | 10.73% | $2.18B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
